Research Analysts Set Expectations for Sanofi Q4 Earnings

Sanofi (NASDAQ:SNY) – Equities research analysts at Leerink Partnrs reduced their Q4 2025 earnings per share (EPS) estimates for shares of Sanofi in a report issued on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn $0.71 per share for the quarter, down from their previous forecast of $0.83. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2026 earnings at $4.73 EPS, FY2027 earnings at $4.93 EPS, FY2028 earnings at $5.23 EPS and FY2029 earnings at $5.69 EPS.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm’s revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.73 EPS.

A number of other analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Barclays reissued an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Trading Up 0.8%

Shares of Sanofi stock opened at $50.14 on Thursday. The firm’s 50 day moving average is $48.18 and its 200 day moving average is $50.15. The firm has a market capitalization of $123.12 billion, a PE ratio of 12.05, a price-to-earnings-growth ratio of 1.18 and a beta of 0.51. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Institutional Trading of Sanofi

Several hedge funds have recently modified their holdings of SNY. Nuveen LLC acquired a new position in shares of Sanofi during the 1st quarter valued at $177,831,000. Raymond James Financial Inc. increased its stake in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after purchasing an additional 1,456,269 shares during the period. OLD Mission Capital LLC bought a new position in shares of Sanofi during the 1st quarter worth about $48,938,000. Finally, Regal Partners Ltd boosted its position in shares of Sanofi by 102.3% during the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock worth $74,794,000 after purchasing an additional 782,838 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.